JP2022512944A5 - - Google Patents

Info

Publication number
JP2022512944A5
JP2022512944A5 JP2021524370A JP2021524370A JP2022512944A5 JP 2022512944 A5 JP2022512944 A5 JP 2022512944A5 JP 2021524370 A JP2021524370 A JP 2021524370A JP 2021524370 A JP2021524370 A JP 2021524370A JP 2022512944 A5 JP2022512944 A5 JP 2022512944A5
Authority
JP
Japan
Prior art keywords
cancer
combination according
antibody
acting
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021524370A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512944A (ja
JP7611136B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060609 external-priority patent/WO2020097556A1/en
Publication of JP2022512944A publication Critical patent/JP2022512944A/ja
Publication of JP2022512944A5 publication Critical patent/JP2022512944A5/ja
Priority to JP2024226179A priority Critical patent/JP2025041784A/ja
Application granted granted Critical
Publication of JP7611136B2 publication Critical patent/JP7611136B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021524370A 2018-11-09 2019-11-08 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬 Active JP7611136B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024226179A JP2025041784A (ja) 2018-11-09 2024-12-23 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862758344P 2018-11-09 2018-11-09
US62/758,344 2018-11-09
US201962789924P 2019-01-08 2019-01-08
US62/789,924 2019-01-08
US201962818003P 2019-03-13 2019-03-13
US62/818,003 2019-03-13
US201962825437P 2019-03-28 2019-03-28
US62/825,437 2019-03-28
US201962843036P 2019-05-03 2019-05-03
US62/843,036 2019-05-03
US201962848372P 2019-05-15 2019-05-15
US62/848,372 2019-05-15
US201962924015P 2019-10-21 2019-10-21
US62/924,015 2019-10-21
PCT/US2019/060609 WO2020097556A1 (en) 2018-11-09 2019-11-08 Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024226179A Division JP2025041784A (ja) 2018-11-09 2024-12-23 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬

Publications (3)

Publication Number Publication Date
JP2022512944A JP2022512944A (ja) 2022-02-07
JP2022512944A5 true JP2022512944A5 (https=) 2022-11-08
JP7611136B2 JP7611136B2 (ja) 2025-01-09

Family

ID=70611137

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524370A Active JP7611136B2 (ja) 2018-11-09 2019-11-08 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬
JP2024226179A Pending JP2025041784A (ja) 2018-11-09 2024-12-23 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024226179A Pending JP2025041784A (ja) 2018-11-09 2024-12-23 別の薬理学的に活性な薬剤と組み合わせた長時間作用型インターロイキン－１５受容体作動薬

Country Status (10)

Country Link
US (1) US20210393742A1 (https=)
EP (1) EP3876974A4 (https=)
JP (2) JP7611136B2 (https=)
KR (1) KR20210090203A (https=)
CN (1) CN112955168A (https=)
AU (1) AU2019376164B2 (https=)
CA (1) CA3119049A1 (https=)
IL (1) IL283020A (https=)
MX (1) MX2021005485A (https=)
WO (1) WO2020097556A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900022590A1 (it) 2019-11-29 2021-05-29 Italtractor Sistema di monitoraggio per sottocarro cingolato
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
EP4346904A1 (en) * 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CN101743249B (zh) * 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2714069A4 (en) * 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc LONG-TERM CONJUGATES WITH TWO HORMONES
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
KR102762243B1 (ko) * 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
WO2016060996A2 (en) * 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2018007304A (es) * 2015-12-21 2019-03-14 Armo Biosciences Inc Composiciones de interleucina-15 y sus usos.
IL270634B2 (en) * 2017-05-15 2025-06-01 Nektar Therapeutics Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Similar Documents

Publication Publication Date Title
JP2022512944A5 (https=)
US20240009196A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
JP7126941B2 (ja) がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
CN105636986B (zh) 包含vegf拮抗剂和抗-ctla-4抗体的组合的方法和组合物
US20200352975A1 (en) Combinations and uses thereof
US20220324965A1 (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
TW202408578A (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
KR20170117113A (ko) 면역 관문 저해제와 조합한 플리나불린의 용도
US20200353077A1 (en) Combinations and uses thereof
HK1251152A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
Blaszczak et al. Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma
US11224654B2 (en) Combinations and uses thereof
CA2797182A1 (en) Methods of enhancing antibody-dependent cellular cytotoxicity
KR20240082379A (ko) 암 치료 방법 및 이의 약제학적 조성물
ES2951864T9 (es) Combinación de un anticuerpo biespecífico ERBB-2/ERBB-3 con terapia endocrina para el cáncer de mama
WO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物
CN120302979A (zh) 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
Mandal Cancer Immunotherapy: Extending New Horizons in Cancer Treatment
JP2024540536A5 (https=)
HK40023127A (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
Revill et al. Catumaxomab
NZ793707A (en) Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
NZ617770B2 (en) Combination therapy with an anti - cd19 antibody and a nitrogen mustard
JP2011074093A (ja) 抗がん剤